Because phase 2 and 3 trials of roxadustat were designed primarily for efficacy and safety evaluation and to meet criteria of guideline-recommended Hb targets, no roxadustat trials to date have compared higher Hb targets with the currently recommended lower Hb targets for CKD patients. This evidence concerns the gene GSTM1 and chronic kidney disease.